Timolol, a nonselective β-adrenergic receptor blocker, is well-tolerated and is becoming increasingly popular in dermatology, especially in the management of infantile haemangioma (IH). Its effects are mainly due to vasoconstriction, inhibition of angiogenesis and keratinocyte migration promotion for re-epithelialization and wound healing. We review the evidence behind the use of timolol in several dermatological conditions including IH, pyogenic granulomas, Kaposi sarcoma, chronic wound healing, postsurgical wounds, acne vulgaris, rosacea, eczema and red scrotum syndrome. © 2021 British Association of Dermatologists.
M Alzaid, A Al-Naseem, F Al-Niaimi, F R Ali. Topical timolol in dermatology: infantile haemangiomas and beyond. Clinical and experimental dermatology. 2022 May;47(5):819-832
PMID: 34798680
View Full Text